CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:The transcription factor Helios restrains the anti-tumor capacity of CD8(+) T cells.
The transcription factor Helios restrains the anti-tumor capacity of CD8(+) T cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
免疫疗法已经彻底改变了癌症治疗,但在一大部分患者中缺乏疗效。因此,理解限制CD8+ T细胞抗肿瘤反应的转录网络至关重要。在这里,我们显示转录因子Helios在人类和小鼠癌症的肿瘤浸润CD8+ T细胞中被诱导。CD8+ T细胞中Helios的基因缺失减少肿瘤生长,减少肿瘤内终末耗竭CD8+ T细胞的数量,并增加具有指示祖细胞能力的转录谱的细胞频率。这些变化与编码干性相关基因的位点染色质可及性增加相关。Helios和PD-1缺陷的组合稳健地改善CD8+ T细胞的抗肿瘤能力。在小分子筛选中鉴定出的Helios抑制剂改善PD-1缺陷的抗肿瘤效果。这些结果表明,Helios代表一个可以增强抗癌免疫疗法的治疗靶点。
Immunotherapy has revolutionized cancer treatment, but it lacks efficacy in a sizable fraction of patients.
Therefore, understanding the transcriptional networks that limit CD8 + T cell anti-tumor responses is fundamental.
Here, we show that the transcription factor Helios is induced in tumor-infiltrating CD8 + T cells in human and murine cancer. Genetic deletion of Helios in CD8 + T cells reduces tumor growth, decreases the number of intratumoral terminally exhausted CD8 + T cells, and increases the frequency of cells with a transcriptional profile indicative of progenitor capacity.
These changes are associated with increased chromatin accessibility in loci encoding stemness-related genes. The combination of Helios and PD-1 deficiencies robustly improves the anti-tumoral capacity of CD8 + T cells. A Helios inhibitor, identified in a small-molecule screen, improves the anti-tumoral effects of PD-1 deficiency. These results demonstrate that Helios represents a therapeutic target that can boost anti-cancer immunotherapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。